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Abstract
Background: The best strategy to protect individuals against meningococcal disease is to immunize against
multiple serogroups. Immunogenicity, antibody persistence, and safety of the EU-licensed meningococcal ACWY-
tetanus toxoid conjugate vaccine (MenACWY-TT) were evaluated in healthy participants aged 11–55 years from the
Philippines and Saudi Arabia.
Methods: In this phase IIb, open, controlled study, 500 participants were randomised (3:1) to receive one dose of
MenACWY-TT or a licensed meningococcal polysaccharide vaccine (Men-PS). Functional antibody responses against
meningococcal serogroups A, C, W-135, and Y were assessed by a serum bactericidal antibody assay using rabbit
complement (rSBA) at Month 0, Month 1, Year 1, Year 2, and Year 3. Vaccine response was defined as an rSBA titre
≥32 at Month 1 in participants who were seronegative (rSBA titre <8) pre-vaccination and as at least a four-fold
increase in titre in participants who were seropositive pre-vaccination. Solicited symptoms were recorded up to Day
4, safety outcomes up to Month 6, and serious adverse events related to vaccination up to Year 3.
Results: Pre-specified criteria for non-inferiority of MenACWY-TT versus Men-PS were met in terms of rSBA vaccine
response and incidence of grade 3 general symptoms. At Month 1, 82.7%–96.3% of MenACWY-TT and 69.7%–91.7%
in Men-PS recipients had a vaccine response for each serogroup. At Year 3, ≥99.1% and ≥92.9% of MenACWY-TT
recipients retained rSBA titres ≥8 and ≥128, respectively, as compared to ≥86.7% and ≥80.0% in the Men-PS group.
Both vaccines had a clinically acceptable safety profile, although injection site redness and swelling were more
frequent in MenACWY-TT recipients.
Conclusions: These results suggest that MenACWY-TT could protect adolescents and adults against meningococcal
disease up to three years post-vaccination.
Trial registration: This study is registered at www.clinicaltrials.gov NCT00356369.
Keywords: Quadrivalent meningococcal vaccine, Conjugate vaccine, Bactericidal activity, Persistence, Safety,
The Philippines, Saudi Arabia
* Correspondence: zmemish@yahoo.com
3College of Medicine, Alfaisal University, PO Box 54146, Riyadh 11514
Saudi Arabia
Full list of author information is available at the end of the article
© 2013 Borja-Tabora et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Borja-Tabora et al. BMC Infectious Diseases 2013, 13:116
http://www.biomedcentral.com/1471-2334/13/116
Background
Neisseria meningitidis is a major cause of endemic and
epidemic invasive bacterial disease worldwide and is as-
sociated with high morbidity [1-3]. Most invasive menin-
gococcal disease is caused by six of the 12 known
serogroups, namely serogroups A, B, C, W-135, Y, and
more recently X [2,3]. The epidemiology of meningococ-
cal disease varies geographically and over time, and the
increasing trend of international travel and migration
facilitates the rapid intercontinental spread of meningo-
coccal isolates [4-7]. Moreover, new strains may also ap-
pear in a region by bacterial capsular switching [3,8].
In Asia and the Middle East, serogroups A, C, and
W-135 are the most common serogroups [3,5,9]. In the
Philippines, an outbreak caused by serogroup A oc-
curred in 2004–2005 [3,10]. A previous outbreak had
been reported in 1989, but data on serogroup distribu-
tion from this earlier outbreak are not available [11]. In
Saudi Arabia, N. meningitidis has been responsible for
various outbreaks during the annual Hajj pilgrimage
[12,13]. An outbreak caused by serogroup A occurred in
1987 and an outbreak caused by serogroup W-135 was
also reported in 2000–2001 [12-15]. Pilgrims to the
Hajj are at increased risk for infection because of
overcrowding, shared living facilities, and close contact
with people from various parts of the world, which are
all known risk factors for meningococcal disease [13].
Immunisation with vaccines against multiple serogroups
is likely to be the best strategy to protect individuals
against meningococcal diseases. In both the Philippines
and Saudi Arabia, vaccination is recommended for indi-
viduals who are at increased risk for meningococcal infec-
tion. In particular, vaccination is used to protect Hajj
pilgrims against invasive meningococcal disease in Saudi
Arabia [5,12]. In response to the 1987 outbreak, vaccin-
ation with a bivalent polysaccharide vaccine against
serogroups A and C was recommended for Hajj pilgrims,
and the vaccination policy was updated following the out-
break in 2000–2001 to include serogroup W-135 [7]. Pres-
ently, Saudi Arabia requires proof of vaccination with a
quadrivalent meningococcal serogroup A, C, W-135, and
Y vaccine to issue Hajj pilgrimage visa for all arrivals.
Moreover, administration of chemoprophylaxis at the port
of entry to all arrivals from the countries of the African
meningitis belt is required in order to lower the carriage
rate among Hajj pilgrims [15,16].
Plain meningococcal polysaccharide vaccines against
serogroups A, C, W-135, and Y are available for use in
adults and children over two years of age. However,
these vaccines are poorly immunogenic for serogroups
C, W-135 and Y, do not elicit long-term protection in
younger children, do not induce immune memory, do
not reduce mucosal carriage (except for serogroup A),
and do not confer herd protection [17-20]. Moreover,
polysaccharide vaccines may induce hyporesponsiveness
to subsequent vaccination, in particular for serogroup
C [17]. To overcome these limitations, capsular polysac-
charides can be coupled to carrier proteins as demon-
strated by monovalent meningococcal serogroup C
conjugate vaccines [21-24]. In 2010, the Ministry of
Health in Saudi Arabia decided to replace the meningo-
coccal polysaccharide vaccines by meningococcal conju-
gate vaccines for Saudi Arabian pilgrims, residents of
Medina and Mecca Regions, and healthcare workers
[12,13]. The introduction of conjugate vaccines, which
have an impact on carriage and transmission of the bac-
teria, could reduce the spread of isolates from asymp-
tomatic pilgrims to their household contacts upon
returning from the pilgrimage [6,14].
Presently, two quadrivalent meningococcal conjugate
vaccines against serogroups A, C, W-135, and Y are li-
censed in various countries [25-27]. Additionally, a new
quadrivalent meningococcal serogroups A, C, W-135,
and Y tetanus-toxoid (TT) conjugate vaccine (Nimenrix™
[GlaxoSmithKline Vaccines]; MenACWY-TT) has been
recently approved by the European Medicines Agency
for individuals aged 12 months and above. Previous stud-
ies have shown that MenACWY-TT is immunogenic and
well-tolerated in toddlers, young children, adolescents,
and young adults [28-34]. In the present study, we com-
pared the immunogenicity and safety of MenACWY-TT
and a licensed quadrivalent meningococcal serogroups A,
C, W-135, and Y plain polysaccharide vaccine in partici-
pants 11–55 years of age in the Philippines and Saudi
Arabia. The study was designed to evaluate the persistence
of the immune response up to five years after vaccination;
results up to the third year were available at the time of
the preparation of this manuscript.
Methods
Study design
This was a phase IIb, open, randomised, controlled study
conducted in two centres in the Philippines (Research In-
stitute for Tropical Medicine and Phillippine General Hos-
pital) and one centre in Saudi Arabia (King Abdulaziz
Medical City in Riyadh). The study consisted of two
phases: the vaccination phase (including the extended
safety follow-up until Month 6) and the long-term persist-
ence phase (up to five years after vaccination). At the time
of the preparation of this manuscript, results up to the
third year post-vaccination were available (covering the
period December 2006 to August 2010).
Participants were randomised (3:1) into two parallel
groups to receive either one dose of the MenACWY-TT
vaccine (ACWY-TT group) or one dose of the MenACWY
polysaccharide vaccine (Men-PS group) at Month 0. The
randomisation list was generated at GlaxoSmithKline
(Rixensart, Belgium) using a standard Statistical Analysis
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System (SASW) program to number the vaccines. Treat-
ment allocation at the investigator sites was performed
using a central internet randomisation system. The ran-
domisation algorithm used a minimisation procedure
(block size of four) accounting for study centre and age of
the subject (11–17 years and 18–55 years of age) in order
to ensure a balanced distribution of the population in each
group (2/3 of subjects were enrolled in the 11–17 year age
stratum, and 1/3 of subjects were enrolled in the 18–55 -
year age stratum). The vaccines were administered in an
open manner due to the differing appearance and route of
administration of the study vaccines.
The study was conducted in accordance with the Good
Clinical Practice Guidelines and the Declaration of
Helsinki. The protocol and associated documents were
reviewed and approved by local ethics committees (the
Institutional Review Board from the National Guard
Health Affair, Riyadh, Saudi Arabia and from the Re-
search Institute for Tropical Medicine, Muntinlupa City,
the University of the Philippines Manila Research Ethics
Board (UPMREB), Manila, the Philippines). Written in-
formed consent was obtained before enrolment from the
participants aged at least 16 years in Saudi Arabia and
18 years in the Philippines. Written informed consent
was obtained from the parents/guardians of younger
participants, and a written informed assent was signed
by these participants. In addition, consent was obtained
if participants in the Philippines reached 18 years of age
during the study. This study is registered at www.
clinicaltrials.gov NCT00356369. A summary of the proto-
col is available at http://www.gsk-clinicalstudyregister.com
(GSK study ID 107386).
Study objectives
The primary objectives of this study were to demon-
strate non-inferiority of the MenACWY-TT vaccine over
the MenACWY polysaccharide vaccine for the entire
population in terms of vaccine response (measured by a
serum bactericidal antibody assay using baby rabbit
serum as exogenous complement source [rSBA]) and in-
cidence of any grade 3 general symptom reported within
four days after vaccination.
The secondary objectives of the study were to compare
the immunogenicity and the persistence of the immune
response of the MenACWY-TT vaccine with that of the
MenACWY polysaccharide vaccine and to evaluate the
reactogenicity and the safety of both vaccines.
Study participants
Study participants were healthy adolescents and adults
from the Philippines and Saudi Arabia aged 11 to 55 -
years at the time of vaccination, who had previously
completed routine childhood vaccinations to the best of
their, or their parents’/guardians’, knowledge.
Participants were excluded if they were immunosup-
pressed from any cause or were previously vaccinated
with a meningococcal conjugate vaccine at any time
or with a meningococcal polysaccharide vaccine against
serogroup A, C, W-135, or Y within five years prior to
the study. Participants with a history of meningococcal
disease due to serogroup A, C, W-135, or Y; Guillain-
Barré syndrome; any neurological disorders or seizures;
allergic disease or reactions likely to be exacerbated by
any component of the vaccine; or chronic alcohol con-
sumption or drug abuse were also excluded. Moreover,
participants were ineligible if they had used an investiga-
tional product within 30 days prior to the study, had
received immunoglobulins or blood products in the pre-
ceding three months, or had a major congenital defect,
serious illness, or acute disease at the time of enrolment.
Females of childbearing potential were required to prac-
tice adequate contraception for 30 days prior to vaccin-
ation, have a negative pregnancy test at the time of
vaccination, and continue contraceptive precautions for
two months after vaccination.
Vaccines
One dose of the MenACWY-TT candidate vaccine
(Nimenrix™, GlaxoSmithKline, Rixensart, Belgium)
contained 5 μg of each of the meningococcal serogroups
A, C, W-135, and Y polysaccharides individually conju-
gated to TT. A single MenACWY-TT vaccine dose was
administered intramuscularly in the non-dominant deltoid
of the participants in the ACWY-TT group. One dose
of the MenACWY polysaccharide vaccine (Mencevax™
ACWY, GlaxoSmithKline, Rixensart, Belgium) contained
50 μg of each of the meningococcal serogroups A, C,
W-135, and Y polysaccharides. A single MenACWY poly-
saccharide vaccine dose was administered subcutaneously
in the non-dominant upper arm of the participants in the
Men-PS group.
Immunogenicity assessment
Blood samples were collected from all participants at
Month 0, Month 1, Year 1, Year 2, and Year 3. Func-
tional antibody responses against meningococcal
serogroups A, C, W-135, and Y were assessed by rSBA
[35]. The target strains used in the rSBA assays were
L10 for serogroup A, C11 for serogroup C, MP01240070
for serogroup W-135, and S-1975 for serogroup Y. rSBA
titres ≥8 for serogroup C are considered to predict pro-
tection [36], and this threshold was extended to the
other serogroups as well [37]. rSBA titres ≥128, a more
conservative correlate of protection, were also evaluated
[38]. Vaccine response was defined as an rSBA titre ≥32
at Month 1 in participants who were seronegative (rSBA
titre <8) at pre-vaccination and as at least a four-fold
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increase in titre from Month 0 to Month 1 in partici-
pants who were seropositive at pre-vaccination.
In addition, antibody concentrations against TT were
determined by enzyme-linked immunosorbent assay
(ELISA) with an assay cut-off of 0.1 IU/mL [39]. All
assays were performed at GlaxoSmithKline’s central la-
boratory (Rixensart, Belgium), and laboratory personnel
were blinded to the treatment group of the subject.
Safety and reactogenicity assessment
Local (pain, redness, and swelling) and general (fatigue,
fever, gastrointestinal symptoms, and headache) solicited
symptoms were recorded during four days and unsoli-
cited adverse events (AEs) during one month after vac-
cination. The intensity of each symptom was graded on
a three-level scale. Injection site redness and swelling
were of grade 3 intensity if their diameter was >50 mm
and fever if oral temperature was >39.5°C. All other
symptoms of grade 3 intensity were defined as symp-
toms preventing normal activity.
New onset of chronic illnesses (NOCIs) and serious
adverse events (SAEs) were recorded for up to six
months post-vaccination. SAEs were defined as any
medical event resulting in death, any life-threatening
event, any event causing disability or requiring hospital-
isation or prolongation of hospitalisation, or any con-
genital anomaly or birth defect in the offspring of a
study participant. Moreover, SAEs related to vaccination
and any events related to lack of vaccine efficacy were
reported throughout the study. All solicited local reac-
tions were considered causally related to vaccination.
Causality of all other AEs was assessed by the investiga-
tors at the local study sites (independent from the Spon-
sor of the study).
Statistical analyses
With a target sample size of 460 participants evaluable
for immunogenicity (345 in the ACWY-TT group and
115 in the Men-PS group), the global power to meet all
the primary objectives of the study was at least 76%.
The total vaccinated cohort, on which the safety ana-
lyses were performed, included all vaccinated partici-
pants. The analyses of immunogenicity were performed
on the according to protocol (ATP) immunogenicity co-
hort and on the ATP cohort for antibody persistence
Year 1, Year 2, and Year 3, which included all evaluable
study participants, who were vaccinated during the vac-
cination phase, meeting the eligibility criteria, with no
elimination criteria during the study, and for whom data
concerning immunogenicity endpoints were available for
at least one tested antigen at Month 1, Year 1, Year 2, or
Year 3, respectively.
The percentages of participants with antibody titres or
concentrations above the proposed cut-offs and with a
vaccine response as well as the geometric mean antibody
titres (GMTs) or geometric mean antibody concentra-
tions (GMCs) for the tested antigens were calculated
with 95% confidence intervals (CIs) in each treatment
group. The GMTs/GMCs were calculated by taking the
anti-log of the mean of the log10 titre/concentration trans-
formations. Antibody titres/concentrations below the cut-
off of the assay were given an arbitrary value of half the
cut-off for the purpose of GMTs/GMCs calculation.
Non-inferiority of the rSBA vaccine response induced
by the MenACWY-TT vaccine over the MenACWY
polysaccharide vaccine was demonstrated if the lower
limit (LL) of the asymptotic standardised 95% CI for the
difference between the ACWY-TT and the Men-PS
groups in the percentage of participants with rSBA vac-
cine response was ≥ −12% for serogroups C, W-135, and
Y and ≥ −15% for serogroup A (inferential analysis).
Potential statistically significant differences between
groups were detected if the asymptotic standardised 95%
CI for the difference in rates (percentages of participants
with titres/concentrations above proposed cut-offs or with
vaccine responses) between the two vaccine groups did
not contain the value “0”, or if the 95% CI for the GMTs/
GMCs ratios between groups did not contain the value “1”
(exploratory analyses). The GMTs/GMCs ratios were
computed by an analysis of covariance model on the log10
transformation of the titres/concentrations using the pre-
vaccination log10 transformation of the titres/concentra-
tions, the age strata, and the vaccine groups as covariates.
No adjustment for multiplicity of secondary endpoints
was made and significant results from the exploratory ana-
lyses should be interpreted with caution.
Non-inferiority of the MenACWY-TT vaccine over the
MenACWY polysaccharide vaccine in terms of incidence
of grade 3 general symptoms was demonstrated if the
upper limit (UL) of the asymptotic 95% CI for the differ-
ence between the ACWY-TT and the Men-PS groups in
the incidence of any grade 3 general symptom within four
days after vaccination was below 5% (inferential analysis).
The percentages of participants reporting each
solicited local and general symptom and each unsolicited
AE were tabulated with exact 95% CIs. NOCIs, SAEs,
and withdrawals due to AEs were described in detail.
The statistical analyses were performed using the
SASW software version 9.1 (SAS Institute Inc., Cary, NC,
United States) and StatXact 7.0.
Results
Study participants
A total of 500 participants were enrolled and vaccinated
in this study; 374 in the ACWY-TT group (225 in the
11–17 years age stratum and 149 in the 18–55 years
age stratum) and 126 in the Men-PS group (76 in the
11–17 years age stratum and 50 in the 18–55 years age
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stratum). Of these, 485, 471, and 460 participants
returned for the Year 1, Year 2, and Year 3 visits, re-
spectively (Figure 1).
The demographic characteristics of the participants in
the total vaccinated cohort were comparable for the two
groups (Table 1). The mean age was 18.8 years, 45.6% of
the participants were female, and the population was
predominantly of South East Asian (79.8%) or of Arabic/
North African (20.0%) heritage.
Immunogenicity
Bactericidal antibodies
Since the LL of the 95% CI on the difference between
the ACWY-TT and the Men-PS groups in the percen-
tage of participants with an rSBA vaccine response was
above −12% for serogroups C, W-135, and Y and above
−15% for serogroup A, the primary objective of non-
inferiority of the vaccine response induced by the
MenACWY-TT vaccine over the MenACWY polysac-
charide vaccine was met for each serogroup (Table 2).
The rSBA vaccine response rates for each of the four
serogroups ranged from 82.7% to 96.3% in the ACWY-
TT group and from 69.7% to 91.7% in the Men-PS
group. Exploratory analyses showed that the rSBA vac-
cine response rates for MenA and MenY were statisti-
cally significantly higher after administration of the
MenACWY-TT vaccine compared with the MenACWY
polysaccharide vaccine for the participants aged 11–55 -
years. Vaccine response rates per age strata are
presented in Additional file 1: Table S1.
4 excluded: Subject previously eliminated (2);
Non compliance with blood sampling schedule (2); 
ATP persistence cohort Year 1: N= 117
Enrolled and vaccinated: N= 500
• 11-17 years age stratum: N=301
• 18-55 years age stratum: N=199
ACWY-TT group
TVC vaccination stage: N=374 
Men-PS group
TVC vaccination stage: N=126 
2 excluded: Administration of forbidden vaccine (2); 
ATP safety cohort Month 1: N= 124
10 excluded: Non compliance with 
blood sampling schedule (10)
ATP immunogenicity cohort Month 1: N= 114
10 withdrawn: Lost to follow-up (3); 
Not willing to participate (7)
Total cohort Year 1: N= 364
5 withdrawn: Lost to follow-up (4); 
Not willing to participate (1)
Total cohort Year 1: N= 121 
8 excluded: Subject previously eliminated (1); 
Non compliance with blood sampling schedule (6); 
Administration of forbidden medication (1)
1 excluded: Administration of forbidden vaccine (1)
ATP safety cohort Month 1: N= 373 
32 excluded: Serological data missing (2);
Non compliance with blood sampling schedule (30); 
ATP immunogenicity cohort Month 1: N= 341
ATP persistence cohort Year 1: N= 356     
20 withdrawn: Lost to follow-up (9); 
Not willing to participate (10); Fatal event (1)
Total cohort Year 2: N= 354
8 excluded: Subject previously eliminated (1); 
Non compliance with blood sampling schedule (5);
Other reason (2)
ATP persistence cohort Year 2: N= 346
5 excluded: Subject previously eliminated (2);
Administration of forbidden vaccine (1);
Non compliance with blood sampling schedule (2)
ATP persistence cohort Year 2: N= 112
9 withdrawn: Lost to follow-up (8); 
Not willing to participate (1)
Total cohort Year 2: N= 117
30 withdrawn: Lost to follow-up (12); 
Not willing to participate (16); Fatal event (2)
Total cohort Year 3: N= 344
6 excluded: Subject previously eliminated (2); 
Non compliance with blood sampling schedule (4)
ATP persistence cohort Year 3: N= 338
10 withdrawn: Lost to follow-up (6);
Not willing to participate (4)
Total cohort Year 3: N= 116
6 excluded: Subject previously eliminated (3); 
Non compliance with blood sampling schedule (3)
ATP persistence cohort Year 3: N= 110
Figure 1 Participant progression through the study. ACWY-TT = group of participants who received one dose of MenACWY-TT at Month 0.
Men-PS = group of participants who received one dose of the MenACWY polysaccharide vaccine at Month 0. ATP = according to protocol.
TVC = total vaccinated cohort. N = number of participants. The numbers of participants withdrawn are given between the TVC vaccination stage
and the total cohort for each timepoint during the persistence phase (Year 1, Year 2, and Year 3).
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At Month 1, at least 99.7% and 99.4% of the recipients
of the MenACWY-TT vaccine reached rSBA titres ≥8
and ≥128 for each of the four serogroups (Table 3). In
both groups, rSBA GMTs were at least 9-fold higher at
Month 1 compared with pre-vaccination. The results in
each of the two age strata were consistent with the re-
sults on the overall study population (Additional file 2:
Table S2). Exploratory analyses did not suggest any sta-
tistically significant difference between the two groups in
the percentages of participants with rSBA titres ≥8 and
≥128, but showed that rSBA GMTs adjusted for pre-
vaccination titres and age strata (in the overall analysis)
were higher after vaccination with MenACWY-TT com-
pared with the MenACWY polysaccharide vaccine for
all four serogroups.
Persistence of the bactericidal antibodies
At Year 3, ≥99.1% and ≥92.9% of the participants in the
ACWY-TT group and ≥86.7% and ≥80.0% in the MenPS
group retained rSBA titres ≥8 and ≥128 for each of the
four serogroups (Table 3). In both groups, the rSBA
GMTs at Year 3 remained higher than the values
observed at Month 0. The rSBA GMTs decay rates were
highest for all four serogroups between Month 1 and
Year 1 (from 2.4- to 5.4-fold in the ACWY-TT group
and from 2.0- to 4.2-fold in the Men-PS group)
(Figure 2). Lower rSBA GMTs decay rates for all four
serogroups were observed between Year 1 and Year 2
(from 1.4- to 1.6-fold in the ACWY-TT group and from
1.5- to 2.2-fold in the Men-PS group) and between Year
2 and Year 3 (from 0.9- to 1.3-fold in the ACWY-TT
group and from 1.0- to 1.2-fold in the Men-PS group).
Exploratory analyses showed that rSBA GMTs ad-
justed for pre-vaccination titres and age strata for
serogroups A, W-135, and Y were statistically signifi-
cantly higher after vaccination with MenACWY-TT
compared with the MenACWY polysaccharide vaccine
up to Year 3 (Additional file 2: Table S2).
Anti-tetanus antibodies
At Month 1, the percentage of participants with anti-TT
concentrations ≥0.1 IU/mL increased from 67.4% (95%
CI: 62.0–72.4) to 95.6% (95% CI: 92.8–97.5) in the
ACWY-TT group and a 28-fold increase of the anti-TT
Table 1 Summary of participant’s demographic characteristics at the time of vaccination
Characteristic ACWY-TT Men-PS
N = 374 N = 126
Age at Month 0 (years) Mean ± SD 18.6 ± 7.62 19.3 ± 8.58
Range 11–53 11–49
Gender Female n (%) 168 (44.9) 60 (47.6)
Male n (%) 206 (55.1) 66 (52.4)
Race South East Asian heritage n (%) 298 (79.7) 101 (80.2)
Arabic/North African heritage n (%) 75 (20.1) 25 (19.8)
East Asian heritage n (%) 1 (0.3) 0 (0.0)
ACWY-TT = group of participants who received one dose of MenACWY-TT at Month 0.
Men-PS = group of participants who received one dose of the MenACWY polysaccharide vaccine at Month 0.
N = number of participants with the administered dose (Total Vaccinated Cohort).
n (%) = number (percentage) of participants with the specified characteristic.
SD = standard deviation.
Table 2 Differences in rSBA vaccine response rate between the ACWY-TT and the Men-PS groups
Antibody ACWY-TT Men-PS Difference in vaccine response rate (ACWY-TT minus Men-PS)
N % N % % [95% CI]
rSBA-MenA 289 82.7 99 69.7 13.00 [3.52, 23.50]
rSBA-MenC 324 94.4 113 90.3 4.18 [−1.03, 11.36]
rSBA-MenW-135 326 96.3 109 91.7 4.58 [−0.07, 11.49]
rSBA-MenY 329 93.0 113 85.0 8.05 [1.72, 16.17]
ACWY-TT = group of participants who received one dose of MenACWY-TT at Month 0.
Men-PS = group of participants who received one dose of the MenACWY polysaccharide vaccine at Month 0.
Vaccine response defined as:
• rSBA titre ≥32 at Month 1 for initially seronegative participants (rSBA titre <8).
• rSBA titre at Month 1 ≥4-fold the antibody titre at Month 0 for initially seropositive participants (rSBA titre ≥8).
N = number of participants with pre- and post-vaccination results available (ATP immunogenicity cohort).
% = percentage of participants with a vaccine response.
95% CI = standardised asymptotic 95% confidence interval.
Bold = lower limits of the 95% confidence intervals of the differences in vaccine response rates, which were used to demonstrate non-inferiority.
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Table 3 Percentage of participants with rSBA titres ≥8 and ≥128 and GMTs before and after vaccination
Group Timing N % ≥8 [95% CI] % ≥128 [95% CI] GMT [95% CI]
rSBA-MenA
ACWY-TT M0 305 95.1 [92.0, 97.2] 89.5 [85.5, 92.7] 330.7 [285.8, 382.7]
M1 323 100 [98.9, 100] 99.7 [98.3, 100] 4944.6* [4451.5, 5492.5]
Y1 354 99.7 [98.4, 100] 99.4 [98.0, 99.9] 2084.9* [1888.3, 2302.0]
Y2 338 99.7 [98.4, 100] 99.1* [97.4, 99.8] 1326.8* [1197.7, 1469.7]
Y3 322 100 [98.9, 100] 99.1* [97.3, 99.8] 1238.4* [1126.0, 1361.9]
Men-PS M0 101 87.1 [79.0, 93.0] 80.2 [71.1, 87.5] 227.8 [162.1, 320.2]
M1 112 100 [96.8, 100] 100 [96.8, 100] 2190.1 [1857.5, 2582.2]
Y1 113 100 [96.8, 100] 99.1 [95.2, 100] 1099.1 [931.6, 1296.7]
Y2 102 99.0 [94.7, 100] 96.1 [90.3, 98.9] 698.9 [561.2, 870.4]
Y3 104 100 [96.5, 100] 94.2 [87.9, 97.9] 596.9 [488.5, 729.3]
rSBA-MenC
ACWY-TT M0 324 78.1 [73.2, 82.5] 53.1 [47.5, 58.6] 84.1 [68.5, 103.4]
M1 341 99.7 [98.4, 100] 99.7 [98.4, 100] 10073.7* [8699.9, 11664.5]
Y1 353 99.7 [98.4, 100] 97.2 [94.9, 98.6] 1848.6 [1620.3, 2109.2]
Y2 345 99.4 [97.9, 99.9] 96.2 [93.6, 98.0] 1162.0 [1013.1, 1332.9]
Y3 337 99.1 [97.4, 99.8] 92.9 [89.6, 95.4] 870.3 [757.1, 1000.4]
Men-PS M0 113 85.0 [77.0, 91.0] 49.6 [40.0, 59.1] 114.1 [80.3, 162.0]
M1 114 100 [96.8, 100] 98.2 [93.8, 99.8] 6545.6 [5047.5, 8488.4]
Y1 115 99.1 [95.3, 100] 95.7 [90.1, 98.6] 1876.5 [1400.7, 2514.0]
Y2 112 98.2 [93.7, 99.8] 92.0 [85.3, 96.3] 1229.4 [876.4, 1724.7]
Y3 109 99.1 [95.0, 100] 93.6 [87.2, 97.4] 1124.8 [812.3, 1557,6]
rSBA-MenW-135
ACWY-TT M0 327 75.5 [70.5, 80.1] 58.4 [52.9, 63.8] 93.0 [74.6, 116.0]
M1 340 99.7 [98.4, 100] 99.4 [97.9, 99.9] 8576.5* [7614.9, 9659.5]
Y1 356 99.7 [98.4, 100] 99.4* [98.0, 99.9] 2993.5* [2618.8, 3421.9]
Y2 346 99.4 [97.9, 99.9] 98.6* [96.7, 99.5] 1984.6* [1757.1, 2241.4]
Y3 336 99.7* [98.4, 100] 98.8* [97.0, 99.7] 2109.2* [1842.5, 2414.5]
Men-PS M0 109 81.7 [73.1, 88.4] 61.5 [51.7, 70.6] 115.3 [81.6, 162.9]
M1 114 100 [96.8, 100] 100 [96.8, 100] 2969.5 [2439.4, 3614.9]
Y1 117 100 [96.9, 100] 94.9 [89.2, 98.1] 699.9 [569.3, 860.4]
Y2 111 90.1 [83.0, 94.9] 81.1 [72.5, 87.9] 319.1 [228.0, 446.5]
Y3 105 86.7 [78.6, 92.5] 80.0 [71.1, 87.2] 332.8 [224.4, 493.8]
rSBA-MenY
ACWY-TT M0 330 92.7 [89.4, 95.3] 80.0 [75.3, 84.2] 310.0 [261.2, 367.9]
M1 340 100 [98.9, 100] 99.7 [98.4, 100] 10315.2* [9317.1, 11420.2]
Y1 355 100 [99.0, 100] 99.7 [98.4, 100] 4207.1* [3767.3, 4698.3]
Y2 345 99.7 [98.4, 100] 99.1* [97.5, 99.8] 3042.1* [2692.2, 3437.5]
Y3 338 99.7 [98.4, 100] 99.4 [97.9, 99.9] 2567.3* [2288.6, 2879.8]
Men-PS M0 113 92.9 [86.5, 96.9] 77.9 [69.1, 85.1] 282.8 [209.9, 380.8]
M1 114 100 [96.8, 100] 100 [96.8, 100] 4573.7 [3863.9, 5413.9]
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GMCs was observed in this group (from 0.35 [95% CI:
0.29 – 0.43] at Month 0 to 10.01 [95% CI: 8.34 – 12.03]
at Month 1). As expected, the percentage of participants
with anti-TT concentrations ≥0.1 IU/mL (60.0% [95% CI:
50.2-69.2] at Month 0 and 56.6% [95% CI: 47.0–65.9]
at Month 1) and the anti-TT GMCs (0.28 [95% CI:
0.20–0.39] at Month 0 and 0.27 [95% CI: 0.19–0.38]
at Month 1) remained stable between pre- and post-
vaccination in the Men-PS group.
Safety/reactogenicity
During the four-day post-vaccination period, grade 3
general symptoms were reported by five participants
(1.3%) in the ACWY-TT group and by no participant in
the Men-PS group (Table 4). The difference between the
ACWY-TT and the Men-PS groups in the incidence of
grade 3 general symptoms was 1.34% (95% CI: -1.64 –
3.09). The non-inferiority of the MenACWY-TT vaccine
over the MenACWY polysaccharide vaccine in terms of
Table 3 Percentage of participants with rSBA titres ≥8 and ≥128 and GMTs before and after vaccination (Continued)
Y1 116 100 [96.9, 100] 98.3 [93.9, 99.8] 1386.5 [1104.2, 1740.9]
Y2 111 99.1 [95.1, 100] 94.6 [88.6, 98.0] 850.2 [667.5, 1082.9]
Y3 108 99.1 [94.9, 100] 97.2 [92.1, 99.4] 848.0 [682.6, 1053.5]
ACWY-TT = group of participants who received one dose of MenACWY-TT at Month 0.
Men-PS = group of participants who received one dose of the MenACWY polysaccharide vaccine at Month 0.
N = number of participants with available results.
% = percentage of participants with titres within the specified range.
GMT = geometric mean titre.
95% CI = 95% confidence interval.
M0 = pre-vaccination blood sample taken at Month 0; M1 = post-vaccination blood sample taken at Month 1 (ATP immunogenicity cohort); Y1 = post-vaccination
blood sample taken at Year 1 (ATP cohort for persistence Year 1); Y2 = post-vaccination blood sample taken at Year 2 (ATP cohort for persistence Year 2); Y3 =
post-vaccination blood sample taken at Year 3 (ATP cohort for persistence Year 3).
*Statistically significantly higher value in the ACWY-TT group compared to the Men-PS group in exploratory analyses.
Figure 2 Reverse cumulative curves for the ACWY-TT and the Men-PS groups for rSBA-MenA (A), rSBA-MenC (B), rSBA-MenW-135 (C),
and rSBA-MenY (D.) ACWY-TT = group of participants who received one dose of MenACWY-TT at Month 0. Men-PS = group of participants who
received one dose of the MenACWY polysaccharide vaccine at Month 0. PRE = pre-vaccination at Month 0; PI(M1) = post-vaccination at Month 1
(ATP immunogenicity cohort); PI(M12) = post-vaccination at Month 12 (ATP cohort for persistence Year 1).
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incidence of any grade 3 general symptom was demon-
strated, as the UL of the standardised asymptotic 95% CI
was below the pre-specified non-inferiority limit of 5%.
Any grade 3 symptoms were reported by 12 participants
(3.2%) in the ACWY-TT group and by one participant
(0.8%) in the Men-PS group (Table 4).
During the four-day follow-up after vaccination, pain
was the most frequently reported solicited local symptom
in both groups (in 143/370 [38.6%] participants in the
ACWY-TT group and 40/124 [32.3%] participants in the
Men-PS group). The most common solicited general
symptom was headache in both groups, which was
reported by 65/371 (17.5%) participants in the ACWY-TT
group and 15/125 (12.0%) participants in the Men-PS
group. Injection site redness and swelling were more fre-
quently reported in the ACWY-TT group (15. 4% and
11.4% respectively) than in the Men-PS group (6.5% and
3.2% respectively) (Figure 3). Grade 3 solicited symptoms
were infrequently reported in both groups and no partici-
pants reported grade 3 fever (oral temperature ≥39.5°C).
During the 6-month extended safety follow-up period,
one participant reported a NOCI (food allergy) and one
participant reported two SAEs (costochondritis and men-
tal disorder). The SAEs were reported in the ACWY-TT
group, but none were considered related to vaccination by
the investigators. No participants reported NOCIs or SAEs
that were considered related to vaccination or events re-
lated to the lack of vaccine efficacy up to three years after
vaccination. In the persistence phase of the study, two par-
ticipants of the ACWY-TT group died due to a traffic acci-
dent (one subject between Year 1 and Year 2 and a second
subject between Year 2 and Year 3).
Table 4 Difference between groups in the percentage of participants reporting grade 3 solicited and unsolicited
symptoms
Symptoms ACWY-TT Men-PS Difference in percentage (ACWY-TT minus Men-PS)
N n % N n % % [95% CI]
Any symptom 374 12 3.2 126 1 0.8 2.41 [−1.29, 4.91]
General symptom 374 5 1.3 126 0 0.0 1.34 [−1.64, 3.09]
Local symptom 374 9 2.4 126 1 0.8 1.61 [−2.06, 3.90]
ACWY-TT = group of participants who received one dose of MenACWY-TT at Month 0.
Men-PS = group of participants who received one dose of the MenACWY polysaccharide vaccine at Month 0.
N = number of participants with the administered dose (total vaccinated cohort).
n/% = number/percentage of participants reporting a specified symptom during the four-day post-vaccination period.
95% CI = standardised asymptotic 95% confidence interval.
Bold = upper limits of the 95% confidence intervals of the differences in percentages of participants reporting grade 3 general symptoms, which were used to


















Pain Redness Swelling Fatigue Fever Gasto-
intestinal
Headache
Figure 3 Percentage of participants in the ACWY-TT and Men-PS groups experiencing solicited local and general symptoms( total
vaccinated cohort). ACWY-TT = group of participants who received one dose of MenACWY-TT at Month 0. Men-PS = group of participants who
received one dose of the MenACWY polysaccharide vaccine at Month 0.% = percentage of participants with at least once the symptom within
the four-day post-vaccination period (total vaccinated cohort). Error bars represent 95% confidence intervals.
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Discussion
Non-inferiority of the immunogenicity of the MenACWY-
TT vaccine as compared to the MenACWY polysacchar-
ide vaccine in terms of rSBA vaccine response to the four
meningococcal serogroups was demonstrated. At one
month post-vaccination, rSBA titres ≥128, which is the
conservative threshold for protection against meningococ-
cal diseases, were reached for each of the four serogroups
by at least 99.4% and 98.2% of the participants vaccinated
with MenACWY-TT and the MenACWY polysaccharide
vaccine, respectively. This observation is consistent with
the results of previous studies in which the immune
response induced by MenACWY-TT was evaluated in
various age groups [28-34]. Moreover, the percentage of
participants who retained rSBA antibody titres ≥8 up to
three years after vaccination remained high for the four
serogroups in both groups, indicating that the protection
continues for at least three years in adolescents and adults.
The high percentage (92.9%) of participants who retained
rSBA titres ≥128 in the present study contrasts with previ-
ous observations, showing waning immunity in terms of
hSBA titres and concerns about the potential for vaccine
failure following vaccination with either the MenACWY
polysaccharide vaccine or another quadrivalent meningo-
coccal conjugate vaccine using diphtheria toxoid as carrier
protein (MenACWY-DT) [40]. However, the two studies
cannot be directly compared since a different assay using
human complement (hSBA) was used in the study with
MenACWY-DT.
Exploratory analyses showed that the rSBA GMTs
for each meningococcal serogroup were statistically sig-
nificantly higher at one month post-vaccination in partici-
pants vaccinated with MenACWY-TT compared with
those who received the MenACWY polysaccharide vac-
cine, although no differences were detected in terms of
percentage of participants with rSBA titres ≥8 or ≥128.
These results are consistent with those of previous studies
conducted on the MenACWY-TTvaccine in children 3–5 -
years of age [29] and in adolescents and young adults [28]
in Europe, and in children [33] and adolescents [34] in
Asia. These results are also in-line with other studies
showing that other quadrivalent meningococcal conjugate
vaccines (MenACWY-DT and MenACWY-CRM197) in-
duce higher antibody titres than plain polysaccharide vac-
cines in children, adolescents, and adults [25,26,41-43].
The rSBA GMTs for serogroups A, W-135, and Y
remained statistically significantly higher in the partici-
pants who received the MenACWY-TT vaccine than in
those who received the MenACWY polysaccharide vac-
cine at three years post-vaccination, while comparable
rSBA GMTs for serogroup C were measured in both vac-
cine groups. The antibody decay for each serogroup was
highest between one month and one year post-vaccination
and the rate of decay decreased at subsequent timepoints
in both groups. These data indicate that decay over time
may lead to the need for further booster doses if the indi-
vidual remains at risk for meningococcal disease. The
evaluation of additional timepoints in the current study
will further contribute to the understanding of the ex-
pected long-term duration of protection.
In this study, high rSBA titres were measured in both
groups at pre-vaccination. This was expected for the age
groups studied (adolescents and adults) because immun-
ity to meningococcal strains is known to increase in an
age-dependent manner [44]. Moreover, the likelihood of
exposure to N. meningitidis and acquisition of functional
antibodies due to natural immunity may vary by location
as meningococcal disease epidemiology varies substan-
tially by geographic area [3]. Vaccine response rate was
chosen as the primary endpoint to evaluate the immuno-
genicity of the vaccines as vaccine response assesses the
ability of participants to respond to the vaccine regard-
less of their serostatus at pre-vaccination. As expected,
immune responses to tetanus toxoid were observed in
the participants who received the MenACWY-TT vac-
cine, but not in those who received the MenACWY
polysaccharide vaccine [28,29,33,34].
Non-inferiority of the MenACWY-TT vaccine over the
MenACWY polysaccharide vaccine, in terms of incidence
of solicited and unsolicited grade 3 general symptoms
reported within four days after vaccination, was demon-
strated. Of note, clinically relevant severe general symp-
toms and vaccine-related events are most likely to occur
during the four-day post-vaccination period. However, the
incidence of any grade 3 symptoms seemed higher in the
participants who received the MenACWY-TT vaccine
than the MenACWY polysaccharide vaccine and this
observation was driven by the local injection site reac-
tions. The specific solicited injection site redness and
swelling with any intensity were also more fre-
quently reported in the participants who received the
MenACWY-TT vaccine than the MenACWY polysac-
charide vaccine. These observations are likely due to
the TT content of the conjugate vaccine and are con-
sistent with previous studies showing that local reac-
tions are more frequent in individuals vaccinated with
quadrivalent meningococcal conjugate vaccines com-
pared to plain polysaccharide vaccines [27-29,33,34,43].
However, we cannot exclude that the intramuscular ad-
ministration of the conjugate vaccine (versus subcutane-
ous for the polysaccharide one) may in part explain the
higher reactogenicity as a previous study suggested that
intramuscular administration of meningococcal polysac-
charide vaccine induced higher rates of erythema com-
pared to subcutaneous administration [45]. No NOCIs
or SAEs reported up to three years after vaccination
were considered related to vaccination in this study and
both vaccines were well-tolerated.
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The present study was limited by its open design due to
the differences in the appearance and administration
mode of the two study vaccines. The open design would
not have influenced the immunogenicity results because
the laboratory personnel was blinded during serological
testing but had the potential to bias the safety reporting in
favour of the control plain polysaccharide vaccine versus
the meningococcal conjugate vaccine. The interpretation
of the results has also been limited by the absence of vali-
dated correlates of protection for serogroups A, W-135,
and Y and by the numerous exploratory statistical com-
parisons, which should be interpreted with caution. The
generalizability of our results was limited by the small
sample size and by the fact that the study was conducted
in two countries. Other studies are being conducted in
parallel to evaluate the immunogenicity and safety of the
MenACWY-TT vaccine in younger age groups and to
compare this vaccine with other licensed quadrivalent
meningococcal conjugate vaccines [30]. Of note, at the
time of study conduct, meningococcal conjugate vaccines
were not licensed in Saudi Arabia or the Philippines.
Conclusion
This study showed that the MenACWY-TT vaccine, when
administered as a single intramuscular dose to adolescents
and adults 11–55 years of age, was non-inferior to a
licensed meningococcal polysaccharide vaccine in terms of
both immunogenicity and safety endpoints. Furthermore,
MenACWY-TT induced an immune response against men-
ingococcal serogroups A, C, W-135, and Y, which persisted
up to three years after vaccination; rSBA GMTs for
serogroups A, W-135, and Y were statistically significantly
higher compared with those in participants who received
the MenACWY polysaccharide vaccine, while comparable
rSBA GMTs for serogroup C were measured in both vac-
cine groups. Both vaccines were well-tolerated and their
safety and reactogenicity profiles were comparable, except
for higher reported rates of injection site redness and swell-
ing after vaccination with MenACWY-TT.
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